A detailed history of Noesis Capital Mangement Corp transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Noesis Capital Mangement Corp holds 116,113 shares of GILD stock, worth $11 Million. This represents 1.93% of its overall portfolio holdings.

Number of Shares
116,113
Previous 111,688 3.96%
Holding current value
$11 Million
Previous $7.66 Billion 27.04%
% of portfolio
1.93%
Previous 1.7%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$66.59 - $83.99 $294,660 - $371,655
4,425 Added 3.96%
116,113 $9.73 Billion
Q2 2024

Aug 05, 2024

BUY
$63.15 - $72.88 $1,263 - $1,457
20 Added 0.02%
111,688 $7.66 Billion
Q1 2024

May 03, 2024

BUY
$71.58 - $87.29 $373,862 - $455,915
5,223 Added 4.91%
111,668 $8.18 Billion
Q4 2023

Feb 06, 2024

SELL
$73.27 - $83.09 $103,164 - $116,990
-1,408 Reduced 1.31%
106,445 $8.62 Billion
Q3 2023

Nov 03, 2023

BUY
$73.94 - $80.67 $37,487 - $40,899
507 Added 0.47%
107,853 $8.08 Billion
Q2 2023

Jul 31, 2023

BUY
$76.01 - $86.7 $8,969 - $10,230
118 Added 0.11%
107,346 $8.27 Billion
Q1 2023

May 08, 2023

BUY
$77.31 - $88.08 $334,365 - $380,946
4,325 Added 4.2%
107,228 $8.9 Billion
Q4 2022

Feb 02, 2023

SELL
$62.32 - $89.47 $261,806 - $375,863
-4,201 Reduced 3.92%
102,903 $8.83 Billion
Q3 2022

Nov 01, 2022

SELL
$59.54 - $68.01 $29,353 - $33,528
-493 Reduced 0.46%
107,104 $6.61 Billion
Q2 2022

Jul 29, 2022

SELL
$57.72 - $65.01 $93,621 - $105,446
-1,622 Reduced 1.49%
107,597 $6.65 Million
Q1 2022

May 05, 2022

SELL
$57.92 - $72.58 $63,654 - $79,765
-1,099 Reduced 1.0%
109,219 $6.49 Million
Q4 2021

Feb 03, 2022

SELL
$64.88 - $73.64 $1.01 Million - $1.15 Million
-15,554 Reduced 12.36%
110,318 $8.01 Million
Q3 2021

Nov 04, 2021

BUY
$67.69 - $73.03 $115,005 - $124,077
1,699 Added 1.37%
125,872 $8.79 Million
Q2 2021

Aug 05, 2021

BUY
$63.47 - $69.35 $19,993 - $21,845
315 Added 0.25%
124,173 $8.55 Million
Q1 2021

May 06, 2021

SELL
$60.0 - $68.46 $206,400 - $235,502
-3,440 Reduced 2.7%
123,858 $8 Million
Q4 2020

Feb 04, 2021

SELL
$56.65 - $64.55 $182,979 - $208,496
-3,230 Reduced 2.47%
127,298 $7.42 Million
Q3 2020

Nov 05, 2020

SELL
$62.1 - $78.08 $178,972 - $225,026
-2,882 Reduced 2.16%
130,528 $8.25 Million
Q2 2020

Aug 07, 2020

SELL
$72.34 - $84.0 $451,473 - $524,244
-6,241 Reduced 4.47%
133,410 $10.3 Million
Q1 2020

May 06, 2020

BUY
$62.63 - $80.22 $23,360 - $29,922
373 Added 0.27%
139,651 $10.4 Million
Q4 2019

Feb 07, 2020

BUY
$61.62 - $67.78 $53,855 - $59,239
874 Added 0.63%
139,278 $9.05 Million
Q3 2019

Nov 05, 2019

BUY
$62.51 - $69.0 $58,196 - $64,239
931 Added 0.68%
138,404 $8.77 Million
Q2 2019

Aug 06, 2019

BUY
$61.87 - $69.38 $57,291 - $64,245
926 Added 0.68%
137,473 $0
Q1 2019

May 09, 2019

BUY
$62.53 - $70.05 $2.32 Million - $2.6 Million
37,112 Added 37.32%
136,547 $0
Q4 2018

Feb 08, 2019

BUY
$60.54 - $79.0 $93,776 - $122,371
1,549 Added 1.58%
99,435 $6.22 Million
Q3 2018

Nov 15, 2018

BUY
$71.28 - $78.92 $340,789 - $377,316
4,781 Added 5.14%
97,886 $7.56 Million
Q2 2018

Aug 13, 2018

SELL
$64.88 - $75.68 $632,060 - $737,274
-9,742 Reduced 9.47%
93,105 $6.6 Million
Q1 2018

May 07, 2018

BUY
$72.84 - $88.8 $184,139 - $224,486
2,528 Added 2.52%
102,847 $7.75 Million
Q4 2017

Feb 14, 2018

SELL
$71.15 - $83.52 $121,310 - $142,401
-1,705 Reduced 1.67%
100,319 $7.19 Million
Q3 2017

Nov 07, 2017

SELL
$72.11 - $85.47 $124,317 - $147,350
-1,724 Reduced 1.66%
102,024 $8.27 Million
Q2 2017

Aug 10, 2017

BUY
N/A
103,748
103,748 $7.34 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $118B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Noesis Capital Mangement Corp Portfolio

Follow Noesis Capital Mangement Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Noesis Capital Mangement Corp, based on Form 13F filings with the SEC.

News

Stay updated on Noesis Capital Mangement Corp with notifications on news.